Course and Correlates of Stigma in Patients on Opioid Agonist Treatment: A Prospective Study from an Outpatient Treatment Program in India

被引:1
作者
Ghosh, Abhishek [1 ]
Roub, Fazle [1 ]
Pillai, Renjith R. [1 ]
Mahintamani, Tathagata [1 ]
Basu, Debasish [1 ]
Subodh, B. N. [1 ]
Mattoo, S. K. [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Drug Deaddict & Treatment Ctr, Dept Psychiat, Sect 12, Chandigarh 160012, India
关键词
Buprenorphine; enacted stigma; internalized stigma; opioid dependence; quality of life; SUBSTANCE USE DISORDERS; INTERNALIZED STIGMA; MENTAL-ILLNESS; SELF-STIGMA; INDIVIDUALS; QUALITY; SCALE; ABUSE; MODEL; LIFE;
D O I
10.1177/02537176211012103
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Individuals with opioid dependence experience stigma and discrimination. Stigma can potentially reduce treatment-seeking and negatively affect treatment outcomes. We aimed to study the course of stigma and its correlates among patients receiving opioid agonist treatment (OAT). Methods: We recruited 51 subjects (aged between 18 and 45 years) registered in the OAT clinic from February to September 2019. We excluded subjects dependent on alcohol and other drugs (except for cannabis and tobacco), with severe mental illness, intellectual disability, and organic brain disease. We assessed the internalized and enacted stigma and quality of life at the treatment entry and after 3 months. Relationship of stigma with quality of life, socio-demographic, and other clinical variables were examined at the treatment entry. Results: Mean age of the subjects was 26.7 (+/- 5) years. At the end of three months, 33 (64.7%) patients were retained in the treatment. Internalized stigma correlated negatively with the social and environmental domains of quality of life. The strength of the correlations was modest. No significant correlation was found between demographic and clinical variables and internalized stigma and enacted stigma scores. Both internalized and enacted stigma scores reduced significantly at 3 months follow-up. The significance levels were retained even after controlling for the baseline quality of life scores. Stigma at the treatment entry did not predict early dropout. Conclusion: Despite higher severity at the treatment entry, the level of internalized and enacted stigma reduced significantly within three months of an outpatient-based OAT program.
引用
收藏
页码:246 / 252
页数:7
相关论文
共 50 条
  • [21] Sleep problems reported by patients entering opioid agonist treatment
    Burke, Christopher K.
    Peirce, Jessica M.
    Kidorf, Michael S.
    Neubauer, David
    Punjabi, Naresh M.
    Stoller, Kenneth B.
    Hursh, Steve
    Brooner, Robert K.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2008, 35 (03) : 328 - 333
  • [22] Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional Study
    von Bernuth, Kira
    Seidel, Peter
    Krebs, Julia
    Lehmann, Marc
    Neumann, Britta
    Konrad, Norbert
    Opitz-Welke, Annette
    FRONTIERS IN PSYCHIATRY, 2020, 11
  • [23] Enacted Stigma From Family and Drug Use During Opioid Use Disorder Treatment
    Earnshaw, Valerie A.
    Brousseau, Natalie M.
    Hill, E. Carly
    Laurenceau, Jean-Philippe
    Sepucha, Karen R.
    Qiu, Xueli
    Mousavi, Mohammad
    Morrison, Lynn M.
    Kelly, John F.
    STIGMA AND HEALTH, 2024,
  • [24] Outpatient methadone maintenance treatment program - Quality of life and health of opioid-dependent persons in Lithuania
    Padaiga, Zilvinas
    Subata, Emilis
    Vanagas, Giedrius
    MEDICINA-LITHUANIA, 2007, 43 (03): : 235 - 241
  • [25] Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study
    Larney, Sarah
    Hickman, Matthew
    Fiellin, David A.
    Dobbins, Timothy
    Nielsen, Suzanne
    Jones, Nicola R.
    Mattick, Richard P.
    Ali, Robert
    Degenhardt, Louisa
    BMJ OPEN, 2018, 8 (08):
  • [26] Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: A longitudinal study
    Tsui, Judith I.
    Anderson, Bradley J.
    Strong, David R.
    Stein, Michael D.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2014, 40 (02) : 163 - 169
  • [27] Postmortem toxicological analyses of blood samples from 107 patients receiving opioid agonist treatment: substances detected and pooled opioid and benzodiazepine concentrations
    Bech, Anne Berit
    Clausen, Thomas
    Waal, Helge
    Vindenes, Vigdis
    Edvardsen, Hilde Eroy
    Frost, Joachim
    Skeie, Ivar
    ADDICTION, 2021, 116 (04) : 845 - 855
  • [28] Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
    Anne Berit Bech
    Thomas Clausen
    Helge Waal
    Jūratė Šaltytė Benth
    Ivar Skeie
    BMC Health Services Research, 19
  • [29] Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
    Bech, Anne Berit
    Clausen, Thomas
    Waal, Helge
    Benth, Jurate Saltyte
    Skeie, Ivar
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
  • [30] The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study
    Bharat, Chrianna
    Larney, Sarah
    Barbieri, Sebastiano
    Dobbins, Timothy
    Jones, Nicola R.
    Hickman, Matthew
    Gisev, Natasa
    Ali, Robert
    Degenhardt, Louisa
    ADDICTION, 2021, 116 (11) : 3139 - 3152